Celltrion (KRX:068270) posted first-half 2026 revenue growth of 18% year-over-year despite a 15% decline in consolidated revenue, as contract manufacturing volumes from third-party clients offset a cyclical slowdown in its own biosimilar product sales. The divergence reflects growing demand for outsourced biologics manufacturing capacity.
Celltrion's CDMO (contract development and manufacturing organization) revenues grew 34% year-over-year as clients accelerated production schedules ahead of anticipated global supply tightening. The biosimilar slowdown reflected inventory normalization at distributors following 2025 build-up.
Celltrion's market capitalisation was ₩43.5 trillion at Thursday's close. Operating margin improved to 15.2% from 11.8% a year earlier as manufacturing utilization rose. The company operates facilities in Incheon and Songdo capable of producing 800,000 liters of biologic drugs annually.
CDMO margins are 35-50% higher than commodity biosimilar production, accelerating consolidation toward pure-play contract manufacturers.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 068270Celltrion, Inc. | ₩188,100 +0.5% |